AstraZeneca's Ticagrelor Gets Positive EU Recommendation, But FDA Could Catch Up Soon
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe's CHMP recommends ticagrelor for patients with acute coronary syndromes, while FDA still grapples with lack of effect in North American patients.
You may also be interested in...
AstraZeneca Says Brilinta Premium Pricing Merited Based On Labeling
During its quarterly earnings call, the pharma pointed out that international reimbursement decisions have supported premium pricing over Plavix.
AstraZeneca Says Brilinta Premium Pricing Merited Based On Labeling
During its quarterly earnings call, the pharma pointed out that international reimbursement decisions have supported premium pricing over Plavix.
AstraZeneca's Brilique Approved In The EU
AstraZeneca's antiplatelet agent Brilique/Brilinta receives its first approval, but pricing negotiations will delay launch in most countries.